Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 1,403 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You acquired 1,403 shares of the firm’s stock in a transaction on Monday, June 23rd. The stock was purchased at an average price of $9.43 per share, for a total transaction of $13,230.29. Following the acquisition, the director now directly owns 28,000 shares in the company, valued at $264,040. This represents a 5.28% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Oric Pharmaceuticals Price Performance

Oric Pharmaceuticals stock traded up $0.69 during midday trading on Monday, hitting $10.00. 814,185 shares of the stock were exchanged, compared to its average volume of 784,830. The stock’s 50-day simple moving average is $6.71 and its 200 day simple moving average is $7.66. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. Sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in shares of Oric Pharmaceuticals by 4.6% in the 4th quarter. Rhumbline Advisers now owns 93,319 shares of the company’s stock valued at $753,000 after purchasing an additional 4,072 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Oric Pharmaceuticals by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 417,955 shares of the company’s stock valued at $3,373,000 after buying an additional 7,726 shares during the period. M&T Bank Corp lifted its position in Oric Pharmaceuticals by 16.6% in the fourth quarter. M&T Bank Corp now owns 99,234 shares of the company’s stock valued at $801,000 after buying an additional 14,097 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Oric Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after buying an additional 2,520 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in Oric Pharmaceuticals by 2,597.8% during the fourth quarter. AlphaQuest LLC now owns 28,435 shares of the company’s stock worth $229,000 after buying an additional 27,381 shares during the period. Institutional investors and hedge funds own 95.05% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ORIC shares. Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their price objective on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Oppenheimer lowered their target price on Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, May 5th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $19.17.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.